Eloxx Pharmaceuticals, Inc. (ELOX) stock
ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$12.75−0.40 (-3.04%)
Close on Nov 16, 2026Market cap $86.56MP/E –Yield –
Eloxx Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Eloxx Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2016 was -$11.10M. For fiscal 2016 it was -$11.10M. The highest annual figure on record is -$4.36M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2016 | Jun 30, 2016 | -$11.10M | – |
| FY2015 | Jun 30, 2015 | -$17.90M | – |
| FY2014 | Jun 30, 2014 | -$8.80M | – |
| FY2013 | Jun 30, 2013 | -$4.36M | – |
| FY2012 | Jun 30, 2012 | -$5.15M | – |
| FY2011 | Jun 30, 2011 | -$7.78M | – |
| FY2010 | Jun 30, 2010 | -$4.72M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$1.38M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$4.87M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$3.73M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$1.12M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$880.91K | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -$1.19M | – |
| Q2 FY2015CQ4 2014 | Dec 31, 2014 | -$10.71M | – |
| Q1 FY2015CQ3 2014 | Sep 30, 2014 | -$5.13M | – |
| Q4 FY2014CQ2 2014 | Jun 30, 2014 | -$3.57M | – |
| Q3 FY2014CQ1 2014 | Mar 31, 2014 | -$2.04M | – |
See a number that looks wrong?